HLS.TO

HLS Therapeutics Inc. [HLS.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HLS.TO Stock Summary

Top 10 Correlated ETFs

HLS.TO

Top 10 Correlated Stocks

HLS.TO

In the News

HLS.TO Financial details

Company Rating
-
Market Cap
165.03M
Income
-27.53M
Revenue
63.07M
Book val./share
-
Cash/share
-
Dividend
0.1
Dividend %
3.35%
Employees
91
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-3.37
Forward P/E
-
PEG
4.92
P/S
1.52
P/B
0.95
P/C
-
P/FCF
6.18
Quick Ratio
1.29
Current Ratio
1.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.68
EPS next Y
-
EPS next Q
-
EPS this Y
16.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
4.87%
Revenue last 5Y
3.09%
Revenue Q/Q
-1.08%
EPS Q/Q
-
-
-
-
-
SMA20
-2.85%
SMA50
4.41%
SMA100
10.1%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-25%
ROC
-0.07%
Gross Margin
89%
Oper. Margin
-21%
Profit Margin
-45%
Payout
-13%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.34-7.12
52W High
-24%
52W Low
+77.33%
RSI
39.03
Rel Volume
2.15
Avg Volume
9.56K
Volume
20.51K
Perf Week
-1.48%
Perf Month
-1.85%
Perf Quarter
10.83%
Perf Half Y
18.49%
-
-
-
-
Beta
1.138
-
-
Volatility
0.08%, 0.11%
Prev Close
-1.66%
Price
5.32
Change
-2.21%

HLS.TO Financial Performance

HLS.TO Dividend History

HLS.TO Frequently Asked Questions

What is HLS Therapeutics Inc. stock symbol ?

HLS Therapeutics Inc. is a CA stock , located in Etobicoke of On and trading under the symbol HLS.TO

What is HLS Therapeutics Inc. stock quote today ?

HLS Therapeutics Inc. stock price is $5.32 today.

Is HLS Therapeutics Inc. stock public?

Yes, HLS Therapeutics Inc. is a publicly traded company.

Something similar

Top by Market Cap
LLY.DE
AVGO
3V64.DE
BRK-B
BRYN.DE
Top Correlated ETFs
HERO.TO
Top Correlated Stocks
MFT.NZ
Similar Market Cap
GROY
BKN
EWZS
ALDEL.PA
MIO.IR

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 9.56K
  • Market Capitalization 165.03M
  • Employee 91
  • CEO Mr. Craig Stuart Millian M.B.A.
  • Headquarters Etobicoke,ON,CA
  • IPO Date 2018-03-14
  • Website https://www.hlstherapeutics.com

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.